CytoMed Therapeutics Stock Forecast

Stock Price Forecast

There have not been any analyst price target forecasts for CytoMed Therapeutics in the last 12 months.

Price Target: n/a

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for CytoMed Therapeutics.

Recommendation Trends

Rating	Jun '24	Jul '24	Aug '24	Sep '24
Strong Buy	0	0	0	0
Buy	1	1	1	1
Hold	0	0	0	0
Sell	0	0	0	0
Strong Sell	0	0	0	0
Total	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Bruce Jackson Benchmark	Benchmark	Buy Reiterates $5	Buy	Reiterates	$5	+410.20%	Oct 10, 2024
Bruce Jackson Benchmark	Benchmark	Buy Reiterates $5	Buy	Reiterates	$5	+410.20%	Jun 11, 2024
Bruce Jackson Benchmark	Benchmark	Buy Reiterates $5	Buy	Reiterates	$5	+410.20%	Dec 4, 2023
Bruce Jackson Benchmark	Benchmark	Buy Initiates $5	Buy	Initiates	$5	+410.20%	Jul 21, 2023

Financial Forecast

Revenue This Year

n/a

from 860.85K

Revenue Next Year

n/a

EPS This Year

n/a

from -0.34

EPS Next Year

n/a

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025
Revenue	113.84K	363.91K	507.74K	503.37K	860.85K
Revenue Growth	91.43%	219.67%	39.52%	-0.86%	71.02%
EPS	-0.30	-0.40	-0.39	-0.22	-0.34
EPS Growth	-	-	-	-	-
Forward PE	-	-	-	-	-
No. Analysts	-	-	-	-	-

Financial currency is SGD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue
High
Avg
Low

Revenue Growth

Revenue Growth
High
Avg
Low

EPS Forecast

EPS
High
Avg
Low

EPS Growth

EPS Growth
High
Avg
Low

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.